AI in Pharma: Faster Therapies, Tighter Oversight
Pharma is under heavier scrutiny than ever. That pressure comes with a payoff: AI is shortening timelines from discovery to approval and may lower development costs.
Over the last two years, AI moved beyond discovery and clinical to touch manufacturing, lab operations, and supply chain. That shift is meaningful for patients, providers, and every team that depends on reliable access to therapies.
Where AI Is Working Now
- Manufacturing: Predictive maintenance, process monitoring, and real-time quality checks reduce deviations and batch failures.
- Lab operations: Automated data capture, experiment planning, and anomaly detection speed up study cycles.
- Supply chain: Demand forecasting, cold-chain monitoring, and allocation models cut stockouts and waste.
- Clinical development: Protocol design, site selection, and patient matching improve trial accuracy and enrollment.
Sandy Donaldson, cofounder, president and chief of strategy at Impiricus, works with dozens of top pharma companies and sees this expansion across the life cycle.
Regulators Are Turning the Screws
Even without a single U.S. federal AI law, oversight is rising. States are pushing new transparency and risk rules, and the EU is cementing stricter obligations for high-risk AI.
- Explainability: Teams must show how AI contributed to a decision, not just the final output.
- Traceability: End-to-end audit trails for data, models, prompts, and model versions are becoming standard.
- Governance: Clear ownership, documented controls, and ongoing monitoring are expected.
Helpful references: the EU's AI Act for high-risk systems and the FDA's thinking on AI in drug development.
- EU AI Act overview (European Parliament)
- FDA discussion paper: AI/ML in drug and biologic development (PDF)
The Payoff for Patients and Providers
- Shorter cycles to market: Better design and trial execution reduce time and budget burn.
- Higher accuracy: Target ID, toxicity prediction, and adaptive trials improve go/no-go decisions.
- More orphan drugs: AI helps find viable matches in small populations, opening up rare disease pipelines.
- Chronic disease coverage: Thousands of conditions with limited options may finally see candidates progress.
What's Holding Teams Back
Strict regulations make change slow. Add the "Not Invented Here" mindset-"we already know how to do it best"-and adoption stalls. Most companies know they need a culture shift, but culture moves only when incentives, tools, and process all line up.
A Practical Playbook for Pharma Leaders
- Stand up model risk governance: Define risk tiers, approvals, and accountability across R&D, clinical, and GxP use cases.
- Build full auditability: Log data lineage, prompts, model versions, parameters, and human overrides.
- Validate like it matters: Pre-specify acceptance criteria, stress test on edge cases, and re-validate after each model update.
- Keep humans in the loop: Require expert review for high-impact decisions (protocols, dose, labeling).
- Vendor diligence: Demand transparency on training data, bias testing, security, and change control.
- Data controls: Pseudonymize early, enforce role-based access, and isolate PHI/PII from model training unless explicitly approved.
- MLOps discipline: Version control, monitoring, drift alerts, and rollback plans across the stack.
- Change management: Update SOPs, train teams, and align incentives to reward compliant adoption.
What This Means for Healthcare Stakeholders
- Providers: Quicker access to new therapies and potentially tighter indications based on more precise evidence.
- Payers: Stronger real-world evidence and modeling will pressure timelines on coverage decisions and outcomes-based contracts.
- Patients: Faster trials and more targeted therapies, especially for rare and long-ignored chronic conditions.
90-Day Quick Wins
- Automate literature triage and evidence summaries for target validation and safety signals.
- Pilot demand forecasting to stabilize critical-drug availability and reduce backorders.
- Use AI schedulers in labs to cut instrument idle time and turn experiments faster.
- Generate draft transparency and compliance reports, then route to legal for review.
- Roll out prompt and review standards; run short workshops to lift team proficiency. For structured upskilling, see AI upskilling resources.
Bottom Line
Oversight will keep getting tougher. That's fine. If you design for transparency, explainability, and auditability from day one, you keep regulators onside and get medicines to patients faster-often at lower cost.
Your membership also unlocks:
